BLEPH-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLEPH-10 (BLEPH-10).
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
| Metabolism | Sulfacetamide undergoes hepatic acetylation and glucuronidation; primarily excreted unchanged in urine. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%). |
| Half-life | Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 40-50% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd of approximately 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Ophthalmic: systemic absorption is low (<5%) following topical ocular administration; oral bioavailability not clinically relevant for this formulation. |
| Onset of Action | Ophthalmic: rapid onset within 30 minutes after instillation. |
| Duration of Action | Ophthalmic: duration of action approximately 4-6 hours following a single dose. |
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment necessary. |
| Liver impairment | No dosage adjustment necessary. |
| Pediatric use | Children: 1 drop every 3-4 hours, or more frequently as directed. |
| Geriatric use | No specific adjustment required; use with caution due to increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BLEPH-10 (BLEPH-10).
| Breastfeeding | Sulfacetamide is excreted into breast milk in small amounts. The M/P ratio for sulfacetamide is not specifically reported; however, for sulfonamides in general, the M/P ratio is around 0.5-0.8. In nursing infants, there is a potential risk of kernicterus, especially in premature or jaundiced infants, or those with G6PD deficiency. The American Academy of Pediatrics considers sulfonamides as compatible with breastfeeding, but caution is advised. Use only if clearly needed. |
| Teratogenic Risk | Sulfacetamide is a sulfonamide antibiotic. During pregnancy, sulfonamides cross the placenta and can theoretically cause kernicterus in the newborn if administered near term, due to displacement of bilirubin from albumin binding sites. First trimester exposure is not clearly associated with major malformations. Risk is highest in the third trimester (after 32 weeks) and during labor. Avoid use during the last trimester unless necessary. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to sulfonamides or any component","Epithelial herpes simplex keratitis","Vaccinia, varicella, or other viral infections of the cornea or conjunctiva","Fungal infections of the eye","Mycobacterial infections of the eye"]
| Precautions | ["Hypersensitivity reactions including Stevens-Johnson syndrome; discontinue at first sign of rash","Prolonged use may lead to overgrowth of nonsusceptible organisms including fungi","Cross-allergenicity with sulfonamides; caution in patients with known sulfa allergy","Ophthalmic use only; not for injection","May cause reversible stinging or burning upon instillation"] |
| Food/Dietary | No known food interactions with ophthalmic sulfacetamide. Avoid alcohol due to theoretical risk of disulfiram-like reaction with systemic sulfonamides (unlikely with ophthalmic use). |
Loading safety data…
| Fetal Monitoring | Monitor for maternal hypersensitivity reactions (rash, fever, Stevens-Johnson syndrome), bone marrow suppression (CBC with differential), and signs of superinfection. In neonates exposed in utero near term, observe for jaundice, bilirubin levels, and signs of kernicterus (lethargy, poor feeding, high-pitched cry). No specific fetal monitoring required for ophthalmic use; however, systemic absorption is minimal after topical application. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies have not reported impairment of fertility. Topical ophthalmic administration results in negligible systemic exposure, making significant reproductive effects unlikely. |
| Clinical Pearls | BLEPH-10 (sulfacetamide sodium ophthalmic solution) is a sulfonamide antibiotic used for ocular infections. It is bacteriostatic against a broad spectrum of gram-positive and gram-negative bacteria. Caution in patients with sulfonamide allergy; cross-sensitivity may occur. Use with caution in patients with dry eye syndrome as the benzalkonium chloride preservative can exacerbate symptoms. Monitor for signs of superinfection with prolonged use. |
| Patient Advice | Do not touch the dropper tip to any surface, including the eye, to avoid contamination. · Shake the bottle well before each use. · Remove contact lenses before instillation; wait at least 15 minutes before reinserting. · Use exactly as prescribed; complete the full course even if symptoms improve. · Report any signs of allergic reaction (rash, itching, swelling) or worsening of eye symptoms. · Avoid driving or operating machinery if vision is temporarily blurred after instillation. |